Latest Hotspot

Upstream Bio begins Phase II trial for Verekitug (UPB-101) in Chronic Rhinosinusitis with Nasal Polyps, treating first patients

9 January 2024
3 min read

Upstream Bio, a biopharmaceutical firm focused on developing innovative treatments for inflammatory conditions, disclosed the initiation of patient treatment in a Phase 2 study, examining the therapeutic potential of verekitug in individuals suffering from chronic rhinosinusitis accompanied by nasal polyps.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Verekitug constitutes a synthetic, fully humanized IgG1 mAb developed to antagonize the thymic stromal lymphopoietin receptor (TLSPR), thereby curbing TSLP-mediated inflammatory processes. TSLP, an inflammatory cytokine, plays a pivotal role in the pathogenesis of CRSwNP, asthma, and several other allergic and inflammatory conditions.

"We are very excited to advance verekitug to a Phase 2 trial in CRSwNP, following the significant and persistent impact we observed on fractional exhaled nitric oxide (FeNO) and circulating eosinophil counts in the recently concluded Phase 1b trial in asthma subjects," remarked Aaron Deykin, MD, the lead of Clinical and Research Development. "The robust results from previous studies provide a foundation for administering verekitug at a minimum 12-week interval," he added.

The Phase 2 study for CRSwNP is a methodically structured, double-masked, placebo-controlled trial that will administer a 100 mg dose of verekitug via subcutaneous injection once every 12 weeks. The trial aims to determine the drug's effectiveness in managing CRSwNP, with the primary measure being the reduction in the severity of nasal polyps. Insights gained from combining the outcomes of Upstream Bio's Phase 2 endeavours in CRSwNP and asthma will shape the dosing regimen for the Phase 3 trials within both conditions.

"The present Phase 2 trial offers Upstream Bio an excellent prospect to showcase verekitug's capacity to serve as a superior biologic agent across a spectrum of allergic and inflammatory ailments," expressed Sam Truex, the company's CEO. "Anticipating that the profound changes in disease markers we detected in the Phase 1b will carry over to the Phase 2 study, we believe CRSwNP patients will significantly benefit from a regimen involving a single injection every 12 weeks."

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序

描述已自动生成 According to the data provided by the Synapse Database, As of January 6, 2024, there are 6 investigational drugs for the TSLPR target, including 5 indications, 7 R&D institutions involved, with related clinical trials reaching 4, and as many as 1007 patents.

Verekitug is a novel recombinant fully human immunoglobulin G1 monoclonal antibody that binds to the human thymic stromal lymphopoietin receptor (TSLPR) to inhibit signaling.UPB-101 is being investigated for its potential in treating asthma and inflammation, as well as other diseases related to the immune system and respiratory system. As it is still in the early stages of development, further research and clinical trials will be needed to determine its safety and efficacy.

图形用户界面, 文本

描述已自动生成

Biological Glossary | What is Specific Region?
Bio Sequence
2 min read
Biological Glossary | What is Specific Region?
9 January 2024
In biology, a specific region typically refers to a specific area within a biological context, such as a particular area on a gene, chromosome, protein, or cell.
Read →
Ventus Therapeutics starts trials on VENT-03, a drug to inhibit cGAS, a novel strategy in its class
Latest Hotspot
3 min read
Ventus Therapeutics starts trials on VENT-03, a drug to inhibit cGAS, a novel strategy in its class
9 January 2024
Ventus Therapeutics has begun trials on VENT-03, an oral drug designed to block cGAS, marking a pioneering approach in this category.
Read →
Biological Glossary | What is Signal Peptide?
Bio Sequence
2 min read
Biological Glossary | What is Signal Peptide?
9 January 2024
A signal peptide is a short peptide (3-60 amino acids) that guides proteins to their designated cellular locations.
Read →
Clinical Trial Outcomes Indicate Similar Efficacy Between Alvotech's Biosimilar AVT06 and Its Comparator, Eylea® (Aflibercept)
Latest Hotspot
3 min read
Clinical Trial Outcomes Indicate Similar Efficacy Between Alvotech's Biosimilar AVT06 and Its Comparator, Eylea® (Aflibercept)
9 January 2024
Alvotech, a global biopharma company specializing in biosimilars, reported positive early results from a key trial of AVT06, its candidate similar to Eylea® (aflibercept).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.